PURPOSE: We investigated the prognostic ability of tumor subtype for patients with breast cancer brain metastases (BCBM) treated with stereotactic radiation (SRT). METHODS: This is a retrospective review of 181 patients who underwent SRT to 664 BCBM from 2004 to 2019. Patients were stratified by subtype: hormone receptor (HR)-positive, HER2-negative (HR+/HER2-), HR-positive, HER2-positive (HR+/HER2+), HR-negative, HER2-positive (HR-/HER2+), and triple negative (TN). The Kaplan-Meier method was used to calculate overall survival (OS), local control (LC), and distant intracranial control (DIC) from the date of SRT. Multivariate analysis (MVA) was conducted using the Cox proportional hazards model. RESULTS: Median follow up from SRT was 11.4 months. Of the 181 patients, 47 (26%) were HR+/HER2+, 30 (17%) were HR-/HER2+, 60 (33%) were HR+/HER2-, and 44 (24%) were TN. Of the 664 BCBMs, 534 (80%) received single fraction stereotactic radiosurgery (SRS) with a median dose of 21 Gy (range 12-24 Gy), and 130 (20%) received fractionated stereotactic radiation therapy (FSRT), with a median dose of 25 Gy (range 12.5-35 Gy) delivered in 3 to 5 fractions. One-year LC was 90%. Two-year DIC was 35%, 23%, 27%, and 16% (log rank, p = 0.0003) and 2-year OS was 54%, 47%, 24%, and 12% (log rank, p < 0.0001) for HR+/HER2+, HR-/HER2+, HR+/HER2-, and TN subtypes, respectively. On MVA, the TN subtype predicted for inferior DIC (HR 1.62, 95% CI 1.00-2.60, p = 0.049). The modified breast-Graded Prognostic Assessment (GPA) significantly predicted DIC and OS (both p < 0.001). CONCLUSIONS: Subtype is prognostic for OS and DIC for patients with BCBM treated with SRT.
PURPOSE: We investigated the prognostic ability of tumor subtype for patients with breast cancer brain metastases (BCBM) treated with stereotactic radiation (SRT). METHODS: This is a retrospective review of 181 patients who underwent SRT to 664 BCBM from 2004 to 2019. Patients were stratified by subtype: hormone receptor (HR)-positive, HER2-negative (HR+/HER2-), HR-positive, HER2-positive (HR+/HER2+), HR-negative, HER2-positive (HR-/HER2+), and triple negative (TN). The Kaplan-Meier method was used to calculate overall survival (OS), local control (LC), and distant intracranial control (DIC) from the date of SRT. Multivariate analysis (MVA) was conducted using the Cox proportional hazards model. RESULTS: Median follow up from SRT was 11.4 months. Of the 181 patients, 47 (26%) were HR+/HER2+, 30 (17%) were HR-/HER2+, 60 (33%) were HR+/HER2-, and 44 (24%) were TN. Of the 664 BCBMs, 534 (80%) received single fraction stereotactic radiosurgery (SRS) with a median dose of 21 Gy (range 12-24 Gy), and 130 (20%) received fractionated stereotactic radiation therapy (FSRT), with a median dose of 25 Gy (range 12.5-35 Gy) delivered in 3 to 5 fractions. One-year LC was 90%. Two-year DIC was 35%, 23%, 27%, and 16% (log rank, p = 0.0003) and 2-year OS was 54%, 47%, 24%, and 12% (log rank, p < 0.0001) for HR+/HER2+, HR-/HER2+, HR+/HER2-, and TN subtypes, respectively. On MVA, the TN subtype predicted for inferior DIC (HR 1.62, 95% CI 1.00-2.60, p = 0.049). The modified breast-Graded Prognostic Assessment (GPA) significantly predicted DIC and OS (both p < 0.001). CONCLUSIONS: Subtype is prognostic for OS and DIC for patients with BCBM treated with SRT.
Entities:
Keywords:
Brain metastases; Breast cancer; Stereotactic radiotherapy; Subtype
Authors: Matthew N Mills; Nicholas B Figura; John A Arrington; Hsiang-Hsuan Michael Yu; Arnold B Etame; Michael A Vogelbaum; Hatem Soliman; Brian J Czerniecki; Peter A Forsyth; Hyo S Han; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2020-02-06 Impact factor: 4.872
Authors: Daniel N Cagney; Nayan Lamba; Sofia Montoya; Puyao Li; Luke Besse; Allison M Martin; Rachel H Brigell; Paul J Catalano; Paul D Brown; Jose P Leone; Shyam K Tanguturi; Daphne A Haas-Kogan; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: Breast Cancer Res Treat Date: 2019-04-13 Impact factor: 4.872
Authors: Ishwaria M Subbiah; Xiudong Lei; Jeffrey S Weinberg; Erik P Sulman; Mariana Chavez-MacGregor; Debu Tripathy; Rohan Gupta; Ankur Varma; Jay Chouhan; Richard P Guevarra; Vicente Valero; Mark R Gilbert; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2015-05-18 Impact factor: 44.544
Authors: Christopher S Grubb; Ashish Jani; Cheng-Chia Wu; Shumaila Saad; Yasir H Qureshi; Tavish Nanda; Andrew Yaeh; Tzlil Rozenblat; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Sameer A Sheth; Jeraldine Lesser; Simon K Cheng; Steven R Isaacson; Andrew B Lassman; Eileen P Connolly; Tony J C Wang Journal: J Neurooncol Date: 2015-11-28 Impact factor: 4.130
Authors: Tamara Z Vern-Gross; Julia A Lawrence; L Douglas Case; Kevin P McMullen; J Daniel Bourland; Linda J Metheny-Barlow; Thomas L Ellis; Stephen B Tatter; Edward G Shaw; James J Urbanic; Michael D Chan Journal: J Neurooncol Date: 2012-09-24 Impact factor: 4.130
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-19 Impact factor: 7.038
Authors: Isabell Witzel; Leticia Oliveira-Ferrer; Klaus Pantel; Volkmar Müller; Harriet Wikman Journal: Breast Cancer Res Date: 2016-01-19 Impact factor: 6.466
Authors: Sebastian Rubino; Daniel E Oliver; Nam D Tran; Michael A Vogelbaum; Peter A Forsyth; Hsiang-Hsuan Michael Yu; Kamran Ahmed; Arnold B Etame Journal: Front Oncol Date: 2022-03-02 Impact factor: 6.244